Prevalence of cardiovascular disorders before and after renal transplantation

Cover Page


Cite item

Full Text

Abstract

Renal transplantation is the optimal approach to management of patients with terminal end-stage renal failure (ESRF). The leading position in the mortality structure of recipients of kidney transplants belongs to cardiovascular disorders. The review analysis the causes and the role of arterial hypertension, myocardial hypertrophy, congestive heart failure, coronary artery disease, and dyslipidemia at different stages of chronic kidney disease (the initial pre-dialysis stage, the hemodialysis or peritoneal dialysis stage, and the post-transplant stage), as well as the possibilities of management of cardiovascular complications. Despite the fact that a  successful transplantation would lead to restoration of the renal function, the prevalence of post-transplant arterial hypertension remains significant and continues to be a major prognostic factor. Arterial hypertension in ESRF patients triggers myocardial and chamber remodeling, mediated by left ventricular hypertrophy. Left ventricular hypertrophy progression due to fibrotic proliferation underlies the systolic and diastolic dysfunction, as well as electrical instability of the myocardium, which leads to such clinical conditions as heart arrhythmias and congestive heart failure. The development of congestive heart failure in transplant recipients has been recognized as an unfavorable prognostic factor. The high prevalence of coronary artery disease among the kidney recipients is related to such risk factors as left ventricular hypertrophy, decreased myocardial contractility, anemia, hypertension, and diabetes mellitus. Screening for coronary artery disease in patients with ESRF awaiting for transplantation, with subsequent preventive revascularization, may reduce perioperative risks of adverse cardiovascular events and improve long-term results of transplantation. Disorders of lipid metabolism related to ESRF are an independent risk factor for coronary atherosclerosis and coronary artery disease. Even after a successful renal transplantation, dyslipidemia remains a  significant problem with its specific characteristics. In addition to its effect on cardiovascular morbidity, the lipid disorders can deteriorate renal function. Identification of potentially reversible risk factors for cardiovascular events and their early management are a  key strategy that determines the life longevity and quality of life in renal transplant recipients. A thorough screening for risk factors in this patient category is necessary to optimize their management.

About the authors

S. M. Martirosyan

Kuban State Medical University; Research Institution “S.V. Ochapovsky Regional Clinic Hospital No. 1”, Ministry of Public Health of the Krasnodar Region

Author for correspondence.
Email: MD.Martirosyan.Krd@mail.ru

MD, Postgraduate Student, Chair of Internal Diseases No. 1, Faculty of Qualification-based Training and Professional ReEducation of Specialists

Cardiologist, Department of Internal Diseases

167 1 Mayа ul., Krasnodar, 350086, Russian Federation.

Tel.: +7 (918) 386 55 00

4 Sedina ul., 350063

167 1 Maya ul., Krasnodar, 350086

Россия

E. D. Kosmacheva

Kuban State Medical University; Research Institution “S.V. Ochapovsky Regional Clinic Hospital No. 1”, Ministry of Public Health of the Krasnodar Region

Email: fake@neicon.ru

MD, PhD, Professor, Chair of Internal Diseases No. 1, Faculty of Qualificationbased Training and Professional Re-Education of Specialists

Assistant Director for Medicine

4 Sedina ul., Krasnodar, 350063

167 1 Maya ul., Krasnodar, 350086

Россия

References

  1. Ватазин АВ, Зулькарнаев АБ. Трансплантация почки как оптимальный метод лечения хронической болезни почек. Лечебное дело. 2013;(3):47–52.
  2. Glicklich D, Vohra P. Cardiovascular risk assessment before and after kidney transplantation. Cardiol Rev. 2014;22(4):153–62. doi: 10.1097/CRD.0000000000000012.
  3. Томилина НА, Волгина ГВ, Бикбов БТ, Ким ИГ. Проблема сердечно-сосудистых заболеваний при хронической почечной недостаточности. Нефрология и диализ. 2003;5(1):15–24.
  4. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension. 2003;42(5):1050–65. doi: 10.1161/01.HYP.0000102971.85504.7c.
  5. Каузер УГ, Риелла МК. Защищая почки, спасаешь сердце. Нефрология и диализ. 2011;13(1):4–7.
  6. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9 Suppl 3:S1–157. doi: 10.1111/j.1600- 6143.2009.02834.x.
  7. Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation. 2006;82(5):603–11. doi: 10.1097/01.tp.0000235527.81917.fe.
  8. Игонин ВА. Состояние функции эндотелия при артериальной гипертензии у больных с ишемической болезнью почек. Вестник Российской военно-медицинской академии. 2007;(S1–1):398.
  9. Шило ВЮ, Хасабов НН, Ермоленко ВМ. Анемия при хронической болезни почек: патогенез, диагностика и лечение. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2008;7(2):28–35.
  10. Stern AB, Klemmer PJ. High-output heart failure secondary to arteriovenous fistula. Hemodial Int. 2011;15(1):104–7. doi: 10.1111/j.1542- 4758.2010.00518.x.
  11. Sarafidis PA, Persu A, Agarwal R, Burnier M, de Leeuw P, Ferro CJ, Halimi JM, Heine GH, Jadoul M, Jarraya F, Kanbay M, Mallamaci F, Mark PB, Ortiz A, Parati G, Pontremoli R, Rossignol P, Ruilope L, Van der Niepen P, Vanholder R, Verhaar MC, Wiecek A, Wuerzner G, London GM, Zoccali C. Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH). Nephrol Dial Transplant. 2017;32(4):620–40. doi: 10.1093/ndt/gfw433.
  12. Azancot MA, Ramos N, Moreso FJ, Ibernon M, Espinel E, Torres IB, Fort J, Seron D. Hypertension in chronic kidney disease: the influence of renal transplantation. Transplantation. 2014;98(5):537–42. doi: 10.1097/TP.0000000000000103.
  13. Nielsen FT, Jensen BL, Hansen PB, Marcussen N, Bie P. The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-term cyclosporine treatment in rat: antagonizing cyclosporine nephrotoxicity. BMC Nephrol. 2013;14:42. doi: 10.1186/1471-2369-14-42.
  14. Carlström M, Wilcox CS, Arendshorst WJ. Renal autoregulation in health and disease. Physiol Rev. 2015;95(2):405–511. doi: 10.1152/physrev.00042.2012.
  15. Kasiske BL, Anjum S, Shah R, Skogen J, Kandaswamy C, Danielson B, O'Shaughnessy EA, Dahl DC, Silkensen JR, Sahadevan M, Snyder JJ. Hypertension after kidney transplantation. Am J Kidney Dis. 2004;43(6):1071–81. doi: 10.1053/j.ajkd.2004.03.013.
  16. Коростовцева ЛС, Звартау НЭ, Конради АО. Выбор антигипертензивного препарата в особых группах пациентов (часть 4): данные доказательной медицины при сопутствующей патологии почек. Артериальная гипертензия. 2014;20(6):510–4. doi: 10.18705/1607-419X-2014-20-6-510-514.
  17. Баев АЕ, Пекарский СЕ, Мордовин ВФ, Крылов АЛ, Ситкова ЕС. Ренальная денервация. Оптимизация техники. Эффективность и безопасность. Международный журнал интервенционной кардиоангиологии. 2013;(35):24.
  18. Дядык АИ, Багрий АЭ, Лебедь ИА, Яровая НФ, Щукина ЕВ, Черний ВВ. Гипертрофия левого желудочка у больных с хронической почечной недостаточностью. Кардиология. 1997;37(2):76–80.
  19. Волгина ГВ. Клиническая эпидемиология кардиоваскулярных нарушений при хронической почечной недостаточности: обзор литературы. Нефрология и диализ. 2000;2(1–2):25–32.
  20. McCullough PA, Chan CT, Weinhandl ED, Burkart JM, Bakris GL. Intensive Hemodialysis, Left Ventricular Hypertrophy, and Cardiovascular Disease. Am J Kidney Dis. 2016;68(5 Suppl 1):S5–14. doi: 10.1053/j.ajkd.2016.05.025.
  21. Шилов ЕН, Фомин ВВ, Швецов МЮ. Хроническая болезнь почек. Терапевтический архив. 2007;79(6):75–8.
  22. Mathew J, Katz R, St John Sutton M, Dixit S, Gerstenfeld EP, Ghio S, Gold MR, Linde C, Shlipak MG, Deo R. Chronic kidney disease and cardiac remodelling in patients with mild heart failure: results from the REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE) study. Eur J Heart Fail. 2012;14(12):1420–8. doi: 10.1093/eurjhf/hfs135.
  23. Stack AG, Mohammed A, Hanley A, Mutwali A, Nguyen H. Survival trends of US dialysis patients with heart failure: 1995 to 2005. Clin J Am Soc Nephrol. 2011;6(8):1982–9. doi: 10.2215/CJN.01130211.
  24. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, Marino P, Oh JK, Popescu BA, Waggoner AD. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4):277–314. doi: 10.1016/j. echo.2016.01.011.
  25. Rigatto C, Parfrey P, Foley R, Negrijn C, Tribula C, Jeffery J. Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol. 2002;13(4):1084–90.
  26. Насыбуллина АА, Булашова ОВ, Хазова ЕВ, Газизянова ВМ, Малкова МИ. Место антагонистов рецепторов ангиотензина II в терапии пациентов с кардиоренальным синдромом. Казанский медицинский журнал. 2015;96(6):1010–4. doi: 10.17750/KMJ2015- 1010.
  27. Корж АН. Кардиоренальный синдром: клиническое значение, критерии диагностики, принципы терапии. Восточно-европейский журнал внутренней и семейной медицины. 2016;(2):37–42. doi: 10.15407/internalmed2016.02.036.
  28. Alnasser SM, Huang W, Gore JM, Steg PG, Eagle KA, Anderson FA Jr, Fox KA, Gurfinkel E, Brieger D, Klein W, van de Werf F, Avezum Á, Montalescot G, Gulba DC, Budaj A, Lopez-Sendon J, Granger CB, Kennelly BM, Goldberg RJ, Fleming E, Goodman SG; GRACE Investigators. Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-up. Am J Med. 2015;128(7):766–75. doi: 10.1016/j.amjmed.2014.12.007.
  29. Sánchez-Perales C, Vázquez-Ruiz de Castroviejo E, Segura-Torres P, Borrego-Utiel F, García-Cortés MJ, García-García F, Biechy-Baldan MM, Gil-Cunquero JM, Liébana-Cañada A. Incidence of acute myocardial infarction in the evolution of dialysis patients [Article in English, Spanish]. Nefrologia. 2012;32(5):597–604. doi: 10.3265/Nefrologia.pre2012.Jun.11464.
  30. Hart A, Weir MR, Kasiske BL. Cardiovascular risk assessment in kidney transplantation. Kidney Int. 2015;87(3):527–34. doi: 10.1038/ki.2014.335.
  31. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol. 2001;12(12):2759–67.
  32. Sud M, Naimark DM. Cardiovascular disease in chronic kidney disease in 2015. Curr Opin Nephrol Hypertens. 2016;25(3):203–7. doi: 10.1097/MNH.0000000000000213.
  33. Fadili W, Habib Allah M, Laouad I. Chronic renal allograft dysfunction: risk factors, immunology and prevention. Arab J Nephrol Transplant. 2013;6(1):45–50.
  34. Mota FM, Araújo J, Arruda JA, Júnior HTS, Pestana JOM, de Sousa JMA, Lima VC. Clinical outcome of renal transplant patients after coronary stenting. Arq Bras Cardiol. 2007;88(5):521–4. doi: 10.1590/S0066- 782X2007000500004.
  35. Hager MR, Narla AD, Tannock LR. Dyslipidemia in patients with chronic kidney disease. Rev Endocr Metab Disord. 2017;18(1):29–40. doi: 10.1007/s11154-016-9402-z.
  36. Kwan BC, Kronenberg F, Beddhu S, Cheung AK. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol. 2007;18(4):1246–61.
  37. Parmar JA, Joshi AG, Chakrabarti M. Dyslipidemia and chronic kidney disease. ISRJ. 2014;3:396–7.
  38. Chen SC, Hung CC, Kuo MC, Lee JJ, Chiu YW, Chang JM, Hwang SJ, Chen HC. Association of dyslipidemia with renal outcomes in chronic kidney disease. PLoS One. 2013;8(2):e55643. doi: 10.1371/journal.pone.0055643.
  39. Tonelli M, Wanner C; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. Ann Intern Med. 2014;160(3):182. doi: 10.7326/M13-2453.
  40. Kidney Disease: Improving Global Outcomes (KDIGO) Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl. 2013;3(3).
  41. Wong MG, Wanner C, Knight J, Perkovic V. Lowering cholesterol in chronic kidney disease: is it safe and effective? Eur Heart J. 2015;36(43): 2988–95. doi: 10.1093/eurheartj/ehv393.
  42. Keane WF, Tomassini JE, Neff DR. Lipid abnormalities in patients with chronic kidney disease: implications for the pathophysiology of atherosclerosis. J Atheroscler Thromb. 2013;20(2):123–33. doi: 10.5551/jat.12849.
  43. Honda H, Hirano T, Ueda M, Kojima S, Mashiba S, Hayase Y, Michihata T, Shishido K, Takahashi K, Hosaka N, Ikeda M, Sanada D, Shibata T. Associations among apolipoproteins, oxidized high-density lipoprotein and cardiovascular events in patients on hemodialysis. PLoS One. 2017;12(5):e0177980. doi: 10.1371/journal. pone.0177980.
  44. Omran J, Al-Dadah A, Dellsperger KC. Dyslipidemia in patients with chronic and end-stage kidney disease. Cardiorenal Med. 2013;3(3): 165–77. doi: 10.1159/000351985.
  45. Neves M, Machado S, Rodrigues L, Borges A, Maia P, Campos M; Grupo Multicêntrico Português de Diálise Peritoneal. Cardiovascular risk in peritoneal dialysis – a Portuguese multicenter study. Nefrologia. 2014;34(2):205–11. doi: 10.3265/Nefrologia.pre2013.Dec.12131.
  46. Riella LV, Gabardi S, Chandraker A. Dyslipidemia and its therapeutic challenges in renal transplantation. Am J Transplant. 2012;12(8):1975– 82. doi: 10.1111/j.1600-6143.2012.04084.x.
  47. Vlachopanos G, Bridson JM, Sharma A, Halawa A. Corticosteroid minimization in renal transplantation: Careful patient selection enables feasibility. World J Transplant. 2016;6(4): 759–66. doi: 10.5500/wjt.v6.i4.759.
  48. Srinivas TR, Oppenheimer F. Identifying endpoints to predict the influence of immunosuppression on long-term kidney graft survival. Clin Transplant. 2015;29(7):644–53. doi: 10.1111/ctr.12554.
  49. Rostaing L, Sánchez-Fructuoso A, Franco A, Glyda M, Kuypers DR, Jaray J. Conversion to tacrolimus once-daily from ciclosporin in stable kidney transplant recipients: a multicenter study. Transpl Int. 2012;25(4):391–400. doi: 10.1111/j.1432-2277.2011.01409.x.
  50. Колина ИБ. Гиперлипидемии при хронической болезни почек: особенности и подходы к лечению. Лечащий врач. 2012;(1):63.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Martirosyan S.M., Kosmacheva E.D.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies